1 / 16

Chemotherapy/ Biotherapy for Hematology Disease Processes

Chemotherapy/ Biotherapy for Hematology Disease Processes. Hematology Disease Processes. Sickle Cell Anemia Immune Thrombocytopenia Purpura Autoimmune Hemolytic Anemia Paroxysmal Nocturnal Hemoglobinuria. Sickle Cell Anemia. Hemoglobinopathy Genetic Disease

jereni
Télécharger la présentation

Chemotherapy/ Biotherapy for Hematology Disease Processes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chemotherapy/Biotherapy for Hematology Disease Processes

  2. Hematology Disease Processes • Sickle Cell Anemia • Immune Thrombocytopenia Purpura • Autoimmune Hemolytic Anemia • Paroxysmal Nocturnal Hemoglobinuria

  3. Sickle Cell Anemia • Hemoglobinopathy • Genetic Disease • Presence of Hemoglobin S, alone or in combination with another abnormal hemoglobin form. • Red blood cell is sickle shaped with a shortened life span

  4. Incidence and Etiology of Sickle Cell Anemia • Most common genetic disorder in the United States (Hgb SS) • Approximately 72,000 cases in United States

  5. Morbidity Associated With Sickle Cell Anemia • Infection • Vaso-occlusive crisis • Acute chest syndrome • Splenic Sequestration • Aplastic Crisis • Cerebral Vascular Accidents

  6. Chronic Complications with Sickle Cell Anemia • Cardiac and Pulmonary Changes • Cholelithiasis • Avascular Necrosis • Renal Impairments • Delayed Growth and Maturation • Impaired Cognition

  7. Immune Thrombocytopenia Purpura • Decrease in platelets • Caused by an immune mediated response • Classified as acute vs. chronic • Often follows viral illness • Can be drug-induced • Chronic ITP often associated with immune disorders

  8. Incidence and Etiology • Equal incidence between boys and girls • Average age 1-10yo • Increase incidence in the winter months

  9. Clinical Presentation • Bruising, petechiae, with or without purpura • Oral or gingival bleeding • Epistaxis • Menorrhagia • Hematuria • Gastrointestinal Bleeding • Recent history of viral illness

  10. Autoimmune Hemolytic Anemia • Decrease hemoglobin due to red blood cell destruction • Immune mediated response • Can be intravascular or extravascular in orgin

  11. Incidence and Etiology • No Known Cause • Incidence is approximately 1 case per 80,000 • Can be associated with other autoimmune conditions (SLE)

  12. Clinical Presentation • Pallor, jaundice • Fatigue or irritability • Tachycardia, palpitations • Dyspnea • Dizziness • Headache • Splenomegaly • Hepatomegaly • Mental impairment, poor concentration, chance in LOC

  13. Paroxysmal Nocturnal Hematuria • Acquired life threatening hematologic disorder • Triad of hemolytic anemia, pancytopenia, and thrombosis • Non-malignant clonal hematopoietic stem cell disorder

  14. Incidence and Etiology • Approximately 8000-10,000 cases in North America and Western Europe • Predominately an adult disease occurring between 30-45 years of age • 10% of cases occur in patients less than 21 years of age • Males and females equally affected

  15. Clinical Presentation of PNH • Fatigue • Abdominal pain • Hematuria • Hemolysis • Thrombosis • Bone Marrow Failure • Dysphagia

  16. References • Essentials of Pediatric Hematology/Oncology Nursing: A Core Curriculum, 3rd Edition, 2008 Editor: Nancy Kline • The Pediatric Chemotherapy and Biotherapy Curriculum, 2nd Edition, 2007 Editor: Nancy Kline

More Related